Microbiota Dysbiosis Linked to Intestinal Cancer Stemness in New Study
New research from National Taiwan University has established a direct connection between gut microbiota dysbiosis and the development of intestinal cancer stemness, particularly in the context of genetic mutations. The study, published in *Gut Microbes* on 17 July 2026, reveals that Apc gene mutations trigger microbiota imbalances, leading to the emergence of invasive *Escherichia coli* strains that activate cancer stemness via the Hippo pathway. This finding challenges the traditional view of mitochondrial dysfunction as a secondary consequence of cancer, instead positioning it as a potential driver of malignant transformation.
The research used mouse models of Apc gene mutation and bacterial-epithelial cell cocultures to demonstrate that invasive *E. coli* enhanced epithelial clonogenicity in genetically predisposed mice. Specifically, the commensal-derived strain *E. coli* LI60C3 increased the size of intestinal organoids in Apc-deficient mice, suggesting microbe-induced stemness. In human colorectal carcinoma tissues, invasive *E. coli* genetic signatures were present in 86% of cases, with a positive correlation between their abundance and the expression of Hippo pathway effectors. These results highlight the interplay between host genetics and microbial factors in cancer progression.
Microbiome as a Therapeutic Target Beyond Genetic Mutations
The study underscores the microbiome’s role as a critical therapeutic target, independent of genetic mutations. While traditional oncology has focused on cellular and genetic alterations, the research positions microbiota dysbiosis as a key contributor to cancer stemness. According to corresponding author Yen-Hsuan Ni, distinguished professor at National Taiwan University, Bacteria-targeting interventions could be an alternative strategy for patients with hereditary tumors.
This aligns with broader efforts to reframe cancer as an emergent property of a destabilized system, influenced by age-related declines in mitochondrial function, immune surveillance, and intestinal barrier integrity.
The findings also emphasize the dynamic relationship between microbiota and host physiology. For example, metabolites from dysbiotic microbiota, such as secondary bile acids, exacerbate oxidative stress and inflammation, creating a feedback loop that accelerates tumorigenesis. This perspective shifts focus from viewing the gut as a passive tissue to recognizing it as an ecosystem where microbial and host factors co-define cancer risk.
Broader Implications for Cancer Research and Treatment
A special issue of *Cancer Biology & Medicine*, guest-edited by Professor Jun Yu of The Chinese University of Hong Kong, further contextualizes these findings within a growing body of research on microbiome-cancer interactions. Published in May 2026, the collection includes seven reviews highlighting the microbiome’s role in hepatocellular, colorectal, gastric, and pancreatic cancers. One review notes that gut dysbiosis—characterized by the loss of *Lactobacillus* and *Akkermansia* and overgrowth of pathogens like *Klebsiella pneumoniae*—drives hepatocarcinogenesis through chronic inflammation. Another outlines a multi-omics framework for decoding host-microbe interactions in colorectal cancer, emphasizing the potential of probiotics and fecal microbiota transplantation (FMT) to modulate immune responses and tumor outcomes.
The research also explores how microbial metabolites can influence immunogenic cell death, potentially converting “cold” tumors into “hot” ones responsive to checkpoint inhibitors. These insights suggest that microbiome science is reshaping cancer care, moving beyond isolated genetic or immunological approaches to integrate host-microbe dynamics. As the authors of the special issue note, The next phase of cancer research isn’t about choosing between genetics, immunology, or microbiology—it’s about understanding how these systems interconnect.
Challenges and Future Directions
Despite these advances, the study acknowledges limitations. Longitudinal data on the conversion of commensal bacteria to pathobionts remain sparse, and the precise mechanisms linking microbiota dysbiosis to stemness require further investigation. Additionally, while the National Taiwan University study found no effect of invasive *E. coli* on wild-type mice, the broader applicability of microbiome-targeted therapies to non-hereditary cancers is yet to be determined.
Nonetheless, the research points to promising avenues for precision oncology. Microbiome-derived biomarkers could enable non-invasive early detection of cancers through stool tests, while probiotics and FMT may enhance the efficacy of immunotherapies. For tumors infected with pathogenic bacteria, targeted antimicrobial strategies could address both infection and malignancy. As the field matures, the integration of microbiome science into cancer care may redefine how researchers and clinicians approach prevention, diagnosis, and treatment.
